Scalper1 News
Shares of biotech Exact Sciences (EXAS) vaulted more than 45% to a new high in early trading on the stock market today after the federal government agreed to reimburse its new colon-cancer test at the rate the company requested. By late morning, Exact Sciences stock was up 33%, near 24. As recently described in a Q&A with CEO Kevin Conroy, Cologuard, the first non-invasive DNA screening test for colon cancer, was approved in August. At the same Scalper1 News
Scalper1 News